Compare ONEW & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONEW | CNTB |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | 2203 | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.1M | 157.1M |
| IPO Year | 2020 | 2021 |
| Metric | ONEW | CNTB |
|---|---|---|
| Price | $11.72 | $2.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $19.00 | $8.50 |
| AVG Volume (30 Days) | 225.1K | ★ 668.7K |
| Earning Date | 01-29-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,872,334,000.00 | $762,000.00 |
| Revenue This Year | $2.33 | N/A |
| Revenue Next Year | $3.44 | $38,289.22 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.63 | N/A |
| 52 Week Low | $10.32 | $0.51 |
| 52 Week High | $22.47 | $3.28 |
| Indicator | ONEW | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 41.98 | 49.55 |
| Support Level | $11.00 | $2.29 |
| Resistance Level | $12.12 | $2.87 |
| Average True Range (ATR) | 0.66 | 0.24 |
| MACD | 0.13 | -0.08 |
| Stochastic Oscillator | 62.28 | 6.06 |
OneWater Marine Inc is a recreational marine retailer in the United States. The company operates in two segments: Dealership and Distribution. The Dealership segment is involved in selling new and pre-owned boats. It also arranges financing and insurance products, provides repairs and maintenance services, offers marine-related parts and accessories, and supplies slip and storage accommodations at certain locations. The Distribution segment focuses on the manufacturing, assembly, and distribution of marine-related products. These products are supplied to distributors, box retailers, and online retailers through a network of warehouses and distribution centers. The company generates the majority of its revenue from the Dealership segment.
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.